background

Pioneering Genetically-Targeted Cardiovascular Therapies

ARCA biopharma’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation (“AF”) in patients with heart failure and reduced left ventricular ejection fraction (“HFREF”) in a genetically defined subpopulation.

ARCA Biopharma Menu
Menu